Skip to content

Velan Capital Investment Management LP

Follow

13F filer, CIK 1848809, ALPHARETTA, GA

Velan Capital Investment Management LP reported $104,739,052 across 43 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 79.85% of the portfolio.

Accepted , ingested 13F-HR 0001848809-26-000006

Period
2026-09-30
Reported value
$105M
Holdings
43
Top 10 weight
79.85%
New
6
Sold out
14

Largest buys vs the previous quarter

SecurityShares changeApprox. value
EDSAadded+454,545$1.91M
EWTXnew+34,250$1.39M
MPLTadded+131,810$1.34M
QTTBnew+120,000$992K
NSPRadded+776,542$519K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
TENXexited-549,985-$8M
RZLTexited-750,000-$3.9M
PRAXreduced-12,181-$3.55M
VRCAexited-471,559-$2.89M
ADMAexited-250,000-$2.09M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001848809-26-000006, largest first. % of portfolio is the value over $104,609,209, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PRAXPRAXIS PRECISION MEDICINES IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 300,000 shares; 2025Q1: 185,000 shares; 2025Q2: 149,334 shares; 2025Q3: 132,805 shares; 2025Q4: 100,781 shares; 2026Q1: 100,781 shares; 2026Q2: 88,781 shares; 2026Q3: 76,600 shares 76,600$22.3M21.33%-12,181Timeline
IMMXIMMIX BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 25,000 shares; 2025Q3: 35,000 shares; 2025Q4: 35,000 shares; 2026Q1: 740,000 shares; 2026Q2: 1,085,000 shares; 2026Q3: 1,085,000 shares 1,085,000$11.3M10.79%0Timeline
TARAPROTARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,579,000 shares; 2025Q1: 1,667,800 shares; 2025Q2: 2,139,000 shares; 2025Q3: 2,139,000 shares; 2025Q4: 2,834,652 shares; 2026Q1: 2,834,652 shares; 2026Q2: 2,844,652 shares; 2026Q3: 2,844,652 shares 2,844,652$8.68M8.29%0Timeline
STROSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 312,000 shares; 2026Q1: 512,160 shares; 2026Q2: 512,160 shares; 2026Q3: 510,038 shares 510,038$8.22M7.85%-2,122Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 64,389 shares; 2025Q4: 67,000 shares; 2026Q1: 77,000 shares; 2026Q2: 65,630 shares; 2026Q3: 65,630 shares 65,630$6.5M6.21%0Timeline
MPLTMAPLIGHT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 522,305 shares; 2026Q1: 492,893 shares; 2026Q2: 492,893 shares; 2026Q3: 624,703 shares 624,703$6.37M6.09%+131,810Timeline
AVRANTERIS TECHNOLOGIES GLOBALQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 700,000 shares; 2026Q2: 700,000 shares; 2026Q3: 700,000 shares 700,000$5.44M5.2%0Timeline
EDSAEDESA BIOTECH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 687,500 shares; 2025Q2: 687,500 shares; 2025Q3: 687,500 shares; 2025Q4: 687,500 shares; 2026Q1: 827,500 shares; 2026Q2: 827,500 shares; 2026Q3: 1,282,045 shares 1,282,045$5.4M5.16%+454,545Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 109,972 shares; 2025Q1: 111,972 shares; 2025Q2: 154,972 shares; 2025Q3: 263,642 shares; 2025Q4: 263,642 shares; 2026Q1: 185,122 shares; 2026Q2: 324,452 shares; 2026Q3: 324,452 shares 324,452$4.97M4.75%0Timeline
XNCRXENCOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 250,000 shares; 2026Q2: 255,000 shares; 2026Q3: 175,000 shares 175,000$4.37M4.17%-80,000Timeline
EVMNEVOMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 506,754 shares; 2026Q1: 446,255 shares; 2026Q2: 451,255 shares; 2026Q3: 456,255 shares 456,255$3.77M3.6%+5,000Timeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 352,000 shares; 2025Q4: 352,000 shares; 2026Q1: 352,000 shares; 2026Q2: 352,000 shares; 2026Q3: 352,000 shares 352,000$3.2M3.06%0Timeline
HRTXHERON THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,986,744 shares; 2025Q1: 6,986,744 shares; 2025Q2: 6,986,744 shares; 2025Q3: 8,753,290 shares; 2025Q4: 8,753,290 shares; 2026Q1: 8,753,290 shares; 2026Q2: 8,753,290 shares; 2026Q3: 8,753,290 shares 8,753,290$2.74M2.62%0Timeline
EWTXEDGEWISE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 34,250 shares 34,250$1.39M1.33%newTimeline
RNTXREIN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,700,000 shares; 2026Q3: 1,700,000 shares 1,700,000$1.37M1.31%0Timeline
NSRXNASUS PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 359,390 shares; 2026Q2: 359,390 shares; 2026Q3: 359,390 shares 359,390$1.33M1.27%0Timeline
QTTBQ32 BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 120,000 shares 120,000$992K0.95%newTimeline
NSPRINSPIREMD INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 904,029 shares; 2025Q1: 904,029 shares; 2025Q2: 904,029 shares; 2025Q3: 2,143,698 shares; 2025Q4: 2,143,698 shares; 2026Q1: 2,099,652 shares; 2026Q2: 148,138 shares; 2026Q3: 924,680 shares 924,680$618K0.59%+776,542Timeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 3,700 shares; 2025Q3: 3,700 shares; 2025Q4: 3,700 shares; 2026Q1: 3,700 shares; 2026Q2: 3,700 shares; 2026Q3: 3,700 shares 3,700$521K0.5%0Timeline
AARDAARDVARK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 85,868 shares 85,868$453K0.43%newTimeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 97,889 shares; 2025Q1: not reported; 2025Q2: 10,000 shares; 2025Q3: 16,000 shares; 2025Q4: 16,000 shares; 2026Q1: 16,000 shares; 2026Q2: 16,000 shares; 2026Q3: 16,000 shares 16,000$379K0.36%0Timeline
CTMXCYTOMX THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 35,000 shares; 2025Q1: 75,000 shares; 2025Q2: 75,000 shares; 2025Q3: 80,000 shares; 2025Q4: 80,000 shares; 2026Q1: 540,000 shares; 2026Q2: 120,000 shares; 2026Q3: 120,000 shares 120,000$326K0.31%0Timeline
OVIDOVID THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 70,000 shares; 2025Q1: 97,000 shares; 2025Q2: 160,000 shares; 2025Q3: 160,000 shares; 2025Q4: 160,000 shares; 2026Q1: 160,000 shares; 2026Q2: 130,000 shares; 2026Q3: 130,000 shares 130,000$324K0.31%0Timeline
MLYSMINERALYS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 150,600 shares; 2025Q2: 174,600 shares; 2025Q3: 175,600 shares; 2025Q4: 151,000 shares; 2026Q1: 11,000 shares; 2026Q2: 11,000 shares; 2026Q3: 11,000 shares 11,000$276K0.26%0Timeline
REPLREPLIMUNE GROUP INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 181,367 shares; 2025Q1: 182,083 shares; 2025Q2: 183,083 shares; 2025Q3: 20,000 shares; 2025Q4: 15,000 shares; 2026Q1: 20,000 shares; 2026Q2: 20,000 shares; 2026Q3: 20,000 shares 20,000$265K0.25%0Timeline
DTILPRECISION BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 20,000 shares; 2025Q4: 20,000 shares; 2026Q1: 40,000 shares; 2026Q2: 40,000 shares; 2026Q3: 40,000 shares 40,000$250K0.24%0Timeline
ZLABZAI LAB LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 9,000 shares 9,000$237K0.23%newTimeline
CCCCC4 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 570,000 shares; 2026Q3: 70,000 shares 70,000$233K0.22%-500,000Timeline
MGNXMACROGENICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 30,000 shares; 2026Q2: 60,000 shares; 2026Q3: 60,000 shares 60,000$232K0.22%0Timeline
IMNMIMMUNOME INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 153,500 shares; 2025Q2: not reported; 2025Q3: 10,000 shares; 2025Q4: 10,000 shares; 2026Q1: 10,000 shares; 2026Q2: 10,000 shares; 2026Q3: 10,000 shares 10,000$215K0.21%0Timeline
ANTXAN2 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 40,000 shares; 2026Q3: 40,000 shares 40,000$213K0.2%0Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 86,500 shares; 2025Q3: 86,500 shares; 2025Q4: 86,500 shares; 2026Q1: 91,123 shares; 2026Q2: 10,000 shares; 2026Q3: 10,000 shares 10,000$206K0.2%0Timeline
CRBPCORBUS PHARMACEUTICALS HLDGSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 56,700 shares; 2025Q1: 59,000 shares; 2025Q2: 59,000 shares; 2025Q3: 61,000 shares; 2025Q4: 13,000 shares; 2026Q1: 26,000 shares; 2026Q2: 26,000 shares; 2026Q3: 30,000 shares 30,000$205K0.2%+4,000Timeline
ENTAENANTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 13,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 15,000 shares 15,000$198K0.19%newTimeline
SCYXSCYNEXIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 40,000 shares; 2026Q3: 40,000 shares 40,000$198K0.19%0Timeline
ARTVARTIVA BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 25,000 shares; 2026Q2: 25,000 shares; 2026Q3: 25,000 shares 25,000$178K0.17%0Timeline
RCKTROCKET PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 294,643 shares; 2026Q2: 60,000 shares; 2026Q3: 60,000 shares 60,000$158K0.15%0Timeline
LYELLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 102,000 shares; 2026Q2: 105,000 shares; 2026Q3: 15,000 shares 15,000$147K0.14%-90,000Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 10,000 shares 10,000$140K0.13%newTimeline
NMRANEUMORA THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 80,000 shares; 2026Q2: 230,000 shares; 2026Q3: 230,000 shares 230,000$137K0.13%0Timeline
LRMRLARIMAR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 18,000 shares; 2025Q1: 28,000 shares; 2025Q2: 33,000 shares; 2025Q3: 33,000 shares; 2025Q4: 33,000 shares; 2026Q1: 33,000 shares; 2026Q2: 33,000 shares; 2026Q3: 33,000 shares 33,000$105K0.1%0Timeline
KLRSKALARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 18,000 shares; 2026Q2: 25,000 shares; 2026Q3: 25,000 shares 25,000$72.2K0.07%0Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
TENXTENAX THERAPEUTICS INC COM NEWcall68,700$130K0

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
TENXTENAX THERAPEUTICS INC549,985$8Mshares
RZLTREZOLUTE INC750,000$3.9Mshares
VRCAVERRICA PHARMACEUTICALS INC471,559$2.89Mshares
ADMAADMA BIOLOGICS INC250,000$2.09Mshares
PROFPROFOUND MED CORP170,278$1.13Mshares
JSPRJASPER THERAPEUTICS INC2,668,395$1.12Mshares
SNDXSYNDAX PHARMACEUTICALS INC10,000$219Kshares
TECXTECTONIC THERAPEUTIC INC6,000$206Kshares
KPTIKARYOPHARM THERAPEUTICS INC20,000$195Kshares
QNRXQUOIN PHARMACEUTICALS LTD32,372$157Kshares
XLOXILIO THERAPEUTICS INC14,285$137Kshares
PRQRPROQR THRAPEUTICS N V45,000$83.7Kshares
CNTXCONTEXT THERAPEUTICS INC59,700$33.1Kshares
GOSSGOSSAMER BIO INC70,000$11.5Kshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001848809-26-000006 base2026-11-16